CB Therapeutics and Atai Life Sciences Launch TryptageniX to Sustainably Supply and Develop Clinically Relevant Compounds to Tackle the Growing Mental Health Crisis

SAN DIEGO, Dec. 09, 2021 (GLOBE NEWSWIRE) — CB Therapeutics, a biosynthesis company focused on creating ethical and environmentally-friendly products to improve mental health and increase healthspan, believes their partnership with atai Life Sciences will help to meet the growing unmet needs of patients with mental health conditions. Read More